Horizon Discovery and Mammoth Biosciences Collaborate To Improve Biotherapeutic Production
Complete the form below to unlock access to ALL audio articles.
Horizon Discovery, a global leader in the application of gene editing and gene modulation technologies, has announced that it has signed a collaboration and license agreement with Mammoth Biosciences, to access Mammoth’s novel CRISPR platform and thereby facilitate delivery of a new generation of genetically engineered CHO cells for the production of biotherapeutics such as therapeutic antibodies.
Horizon’s bioproduction business unit currently offers the biopharmaceutical industry a well-characterized CHO cell line and customized services to facilitate the development and identification of best performing gene-edited cell lines.
Under the terms of the agreement, the companies will collaborate to optimize certain CRISPR tools to rapidly develop proprietary CHO cell lines. In these cell lines, selected genes are “knocked out” to improve performance parameters such as increasing productivity or reducing naturally occurring contaminants to facilitate purification.
Mammoth Biosciences is a San Francisco based biotech company that has built the first CRISPR-based detection platform for diagnostics. Mammoth’s novel CRISPR platform can be used and built on by partners across a variety of industries. Its DETECTR biosensing platform acts as a search engine for biology, capable of sensing any nucleic acid-based biomarker, including markers for early detection of diseases ranging from infections to cancer.